UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM SD
Specialized Disclosure Report
NAVIDEA BIOPHARMACEUTICALS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-35076
|
|
31-1080091
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
4995 Bradenton Avenue, Suite 240, Dublin, Ohio
|
|
43017-3552
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Jed A. Latkin, (614) 793-7500
|
(Name and telephone number, including area code, of the person to
contact in connection with this report.)
|
Check
the appropriate box to indicate the rule pursuant to which this
form is being filed, and provide the period to which the
information in this form applies:
☒
Rule 13p-1 under
the Securities Exchange Act (17 CFR 240.13p-1) for the reporting
period from
January
1 to December 31, 2016
.
Section 1 – Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure
Navidea
Biopharmaceuticals, Inc. (the Company) has evaluated its current
product line to determine whether it manufactures or contracts to
manufacture any products for which columbite-tantalite (colta),
cassiterite, gold, wolframite, or their derivatives are necessary
to the functionality of the product. The Company has determined
that its Tc 99m tilmanocept product (the Covered Product) contains
tin, a derivative metal from the mineral cassiterite.
The
Company has conducted a reasonable country of origin inquiry (RCOI)
as required by the Dodd-Frank Wall Street Reform and Consumer
Protection Act. The Company’s RCOI consisted of submitting
inquiries to its supplier of the Covered Product. The Company has
relied on the certification from an upstream supplier of its
supplier that the tin used in the Covered Product did not originate
from the Democratic Republic of Congo or an adjoining
country. The Company has no reason to believe that this
certification is inaccurate. Accordingly, the Company has
determined that the tin contained in the Covered Product did not
originate from the Democratic Republic of Congo or an adjoining
country.
A copy
of this Conflict Minerals Disclosure is publicly available at
www.navidea.com
under “Investors,” then “Conflict Minerals
Disclosure.”
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the duly authorized undersigned.
|
|
|
Navidea
Biopharmaceuticals, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
/s/ Jed
A. Latkin
|
|
May 31,
2017
|
By
(Signature and Title)
|
|
(Date)
|
Jed A.
Latkin
|
|
|
Chief
Operating Officer and Chief Financial Officer
|
|
|